
Melanoma and Other Skin Cancers:

Biology and Patient Management 2020



November 7, 2020

A Virtual Conference

Course Director:

GEOFFREY T. GIBNEY, MD

MedStar Georgetown University Hospital Georgetown Lombardi Comprehensive Cancer Center Washington, D.C.

Course Co-Directors:

MICHAEL B. ATKINS, MD

MedStar Georgetown University Hospital Georgetown Lombardi Comprehensive Cancer Center Washington, D.C.

WADDAH B. AL-REFAIE, MD, FACS

MedStar Georgetown University Hospital Georgetown Lombardi Comprehensive Cancer Center Washington, D.C.

VESNA M. PETRONIC-ROSIC, MD, MSC, MBA

MedStar Georgetown University Hospital MedStar Washington Hospital Center Washington, D.C.



Continuing Education Credit Information

Course Description

In this interdisciplinary conference, an expert, international faculty will present clinical updates in melanoma biology, staging and early disease management. This includes novel approaches to melanoma detection and risk prediction. In addition, exciting advances in the treatment of patients with high-risk and metastatic disease will be discussed with a special emphasis on the multidisciplinary approach to the care of patients with melanoma. Other sessions will feature new data on the role of neoadjuvant and adjuvant therapy, the management of patients with brain metastases and leptomeningeal disease, duration of systemic therapy, changes in the role of surgery and the impact of various prognostic and predictive biomarkers on patient management. Concluding the day will be a session examining the latest approaches to the management of non-melanoma skin cancers. Case presentations and debates will address complex and controversial management issues in patients with high-risk and advanced melanoma and non-melanoma skin cancer.

Learning Objectives

Physicians

- Analyze and apply new insights in the diagnosis and treatment of advanced melanoma.
- Use appropriate staging modalities correctly gauge patient risk of recurrence and death and choose the most appropriate patient care strategy.
- Discuss evolving research and treatment options for patients with disease resistant to IO +/-BRAF/MEK inhibitor therapy.
- Recognize the value of multidisciplinary evaluation and assessment, in contributing to more
 effective and expedited patient treatment.
- Assess new data on molecularly targeted therapies and novel immunotherapy in order to develop integrated treatment plans for patients with various molecular subtypes and stages of disease.
- Incorporate salvage surgery and targeted radiation in selected patients to enhance long term outcomes.
- Recognize the changing role in completion lymph node dissection.
- Describe the new data on choice of combination vs. single agent immunotherapy.
- Apply new data on adjuvant and neoadjuvant therapy.
- Recognize new approaches to the management of patients with brain metastases and leptomeningeal disease.
- Analyze and apply new insights in the treatment of non-melanoma skin cancers.

Nurses

- Identify appropriate surgical interventions/indications for patients with melanoma and nonmelanoma skin cancers.
- Identify indications for radiographic studies including PET and CT scans in staging and evaluating response.
- Explain the role of radiation therapy in the adjuvant and metastatic settings.
- Recognize systemic treatment modalities for melanomas and non-melanoma skin cancers in the adjuvant and metastatic settings including immunotherapy, targeted agents and vaccines.

Target Audience

This conference is intended for radiologists, dermatologists, oncologists, pathologists, plastic surgeons, radiation oncologists, medical oncologists, residents, fellows, physician assistants, nurse practitioners, nurses, medical students, and other members of the healthcare team interested in the management of melanoma and other skin cancers.

Accreditation



In support of improving patient care, MedStar Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designation



This activity was planned by and for the healthcare team, and learners will receive 6.25 Interprofessional Continuing Education (IPCE) credits for learning and change.

Physicians: MedStar Health designates this live activity for a maximum of 6.25 *AMA PRA Category 1 Credits* TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: This activity is approved for 6.25 ANCC contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.



Course Director

Geoffrey T. Gibney, MD

Co-Leader, Melanoma Disease Group Georgetown Lombardi Comprehensive Cancer Center MedStar Georgetown University Hospital Washington, D.C.

Course Co-Directors

Michael B. Atkins, MD

Deputy Director Georgetown Lombardi Comprehensive Cancer Center William M. Scholl Professor and Vice Chair, Oncology Georgetown University Medical Center Staff Physician, Division of Hematology/Oncology MedStar Georgetown University Hospital MedStar Washington Hospital Center Washington, D.C.

Waddah B. Al-Refaie, MD, FACSJohn S. Dillon Professor and Regional Chief of Surgical Oncology Georgetown University Medical Center MedStar Georgetown University Hospital Surgeon-in-Chief, Georgetown Lombardi Comprehensive Cancer Center Vice Chair for Research Washington, D.C.

Vesna M. Petronic-Rosic, MD, MSc, MBA

Physician Executive Director, Dermatology MedStar Health MedStar Washington Hospital Center MedStar Georgetown University Hospital Professor and Founding Chair, Dermatology Georgetown University Medical Center Washington, D.C.

Keynote Speaker

Christian Blank, MD, PhD

Group Leader, Molecular Oncology & Immunology Netherlands Cancer Institute Amsterdam, Netherlands

Faculty

Clara Curiel-Lewandrowski, MD

Director, Multidisciplinary Cutaneous Oncology Program Chief, Division of Dermatology The Alan and Janice Levin Family Endowed Chair for Excellence in Cancer Research Professor, Dermatology University of Arizona Health Sciences Tucson, AZ

Min Deng, MD

Director, Mohs Micrographic Surgery MedStar Washington Hospital Center MedStar Georgetown University Hospital Assistant Professor, Dermatology Georgetown University Medical Center Washington, D.C.

Isabella C. Glitza Oliva, MD, PhD, MS

Associate Professor, Melanoma Medical Oncology Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston, TX

Douglas Grossman, MD, PhD

Co-Leader, Melanoma Center Huntsman Cancer Institute Professor, Dermatology Adjunct Professor, Oncological Sciences University of Utah Salt Lake City, UT

Amod S. Sarnaik, MD

Surgical Oncologist, Cutaneous Oncology Immunology Program and the Melanoma Center of Excellence Moffitt Cancer Center Tampa, FL

Ryan J. Sullivan, MD

Assistant Professor, Medicine Harvard Medical School Assistant Professor, Hematology/Oncology Massachusetts General Hospital Boston, MA



Agenda

8:00 a.m. Welcome and Introduction 11:15 a.m. The Changing Role of Surgery in Waddah B. Al-Refaie, MD, FACS High-Risk and Metastatic Melanoma SESSION I: Management of Early Stage Waddah B. Al-Refaie, MD, FACS Melanoma Session Chair: Waddah B. Al-Refaie, MD, FACS 11:40 a.m. Panel Discussion and Questions Moderator: Geoffrey T. Gibney, MD Panelists: W. Al-Refaie, C. Blank Clinical Dermatologic 8:05 a.m. Evaluation, New and Future **Melanoma Detection** 12:00 p.m. Afternoon Break and Visit with Techniques (Melanoma Skin the Exhibitors Exams/Artificial Intelligence in Skin Exams) **SESSION III: Current Challenges in** Clara Curiel-Lewandrowski, MD Advanced Disease Session Chair: Michael B. Atkins, MD Pathology of Melanoma: Current 8:25 a.m. Status and Prognostic Indicators **Update on Frontline Systemic** 1:00 p.m. Vesna M. Petronic-Rosic, MD, MSc, MBA Therapy Michael B. Atkins, MD 8:45 a.m. **Molecular Prognostic Tests for** Melanoma Treatment Decision **Cellular Therapy Program** 1:20 p.m. Amod S. Sarnaik, MD Douglas Grossman, MD, PhD Novel Second/Third Line 1:40 p.m. 9:05 a.m. Mohs Surgery for Skin Cancers **Treatment Options** Min Deng, MD Ryan J. Sullivan, MD Panel Discussion and Questions 9:25 a.m. Treatment of Brain Metastases/ 2:00 p.m. Moderator: IMD Waddah B. Al-Refaie, MD, FACS Isabella C. Glitza Oliva, MD, PhD, MS Panelists: C. Curiel-Lewandrowski, M. Deng, D. Grossman, **Update on Systemic Therapies** 2:25 p.m. V. Petronic-Rosic for Non-Melanoma Skin Cancers Geoffrey T. Gibney, MD Morning Break and Visit with 9:45 a.m. the Exhibitors Panel Discussion and Questions 2:45 p.m. Moderator: Michael B. Atkins, MD **SESSION II:** Surgical and Neoadjuvant/ Panelists: G. Gibney, I. Glitza Oliva, **Adjuvant Therapeutic Approaches** A. Sarnaik, R. Sullivan Session Chair: Geoffrey T. Gibney, MD **Closing Remarks** 3:05 p.m. **KEYNOTE LECTURE:** Geoffrey T. Gibney, MD Neoadjuvant vs. Adjuvant Therapy: Surgical and Medical 3:15 p.m. Adjourn Perspectives Christian Blank, MD, PhD **Novel Adjuvant Therapy** 11:00 a.m.

Protocols

Geoffrey T. Gibney, MD

Registration Information

Registration is complementary for healthcare providers and professionals!

Physician	\$0
Physician Assistant	\$0
Resident and Fellow	\$0
Nurse Practitioner	\$0
Nurse	\$0
Allied Health Professional	\$0

Online Registration Preferred

Please visit **CE.MedStarHealth.org/Melanoma** for updated program and registration information. Please call 202-780-1655 for further instructions.

All registrations will be confirmed by email only. If you have questions or do not receive a confirmation within 1-2 business days, please contact us at medstarcpe@medstar.net or 202-780-1655.

Cancellation Policy

If you are unable to attend the date of the conference, your paid registration fee will still grant you access to conference slides and recorded content. CE hours will be credited based on attendance day of or completion of recorded content.

Conference Information

This conference is taking place online with live speakers and Q&A sessions.

Special Assistance

MedStar Health wishes to ensure that no individual with a disability is excluded, denied services, segregated or otherwise treated differently from other individuals because of the absence of auxiliary aids or services identified in the Americans with Disabilities Act. Please contact 202-780-1655 to notify us of your needs.

For grant and exhibit support information please contact Ada Guo at ada.guo@medstar.net